Biomarker assays are developed specifically for pharmacokinetic and pharmacodyamic (PK/PD) models during drug discovery and are often used to test efficacy and toxicity. Inhibitors of PI3K, SYK and BTK pathways are a large focus for pharmaceutical companies with several small molecule inhibitors currently at different stages of development. This process can present many challenges in trying to capture all the information about the entire signaling pathways controlled by these kinases due to the limitations of enzymatic assays.
View the BÜHLMANN eBook pertaining to basophil activation for a dynamic overview with insights on overcoming limitations in drug development, using basophils as biomarker and Flow CAST® as your tool of choice.
